Clinical research

Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial

EuroIntervention 2012;7:1060-1061 publish onlinea ahead of print September 2011. DOI: 10.4244/EIJV7I9A168

Dariusz Dudek
Dariusz Dudek1*, MD; Yoshinobu Onuma2, MD; John A. Ormiston3, MD; Leif Thuesen4, MD; Karine Miquel-Hebert5, PhD; Patrick W. Serruys2, MD, PhD
1. Jagiellonian University Medical College, Krakow, Poland; 2. Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 3. Auckland City Hospital, Auckland, New Zealand; 4. Skejby Sygehus, Aarhus University Hospital, Skejb

Aims: The first-in-man ABSORB Cohort A trial demonstrated the bioresorption of the ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA) at two years. This report describes

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bioresorbable scaffoldcoronary artery diseaselong-term outcome
Read next article
Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry

Latest news